Vor Biopharma Inc. (VOR) stock
VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$19.42+0.10 (+0.52%)
Close on Nov 13, 2026Market cap $1.19BP/E –Yield –
Vor Biopharma cash
Cash and short-term investments held at the end of each period.
Vor Biopharma's cash was $481.60M at Sep 30, 2026. For fiscal 2025 it was $455.20M, up 395.3% from the year before. The highest annual figure on record is $455.20M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $455.20M | +395.3% |
| FY2024 | Dec 31, 2024 | $91.90M | -33.0% |
| FY2023 | Dec 31, 2023 | $137.18M | -40.4% |
| FY2022 | Dec 31, 2022 | $230.25M | +11.0% |
| FY2021 | Dec 31, 2021 | $207.47M | +327.4% |
| FY2020 | Dec 31, 2020 | $48.54M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $481.60M | +182.5% |
| Q2 FY2026 | Jun 30, 2026 | $466.10M | +132.4% |
| Q1 FY2026 | Mar 31, 2026 | $491.50M | +719.2% |
| Q4 FY2025 | Dec 31, 2025 | $455.20M | +395.3% |
| Q3 FY2025 | Sep 30, 2025 | $170.50M | +171.5% |
| Q2 FY2025 | Jun 30, 2025 | $200.60M | +133.5% |
| Q1 FY2025 | Mar 31, 2025 | $60.00M | -44.2% |
| Q4 FY2024 | Dec 31, 2024 | $91.90M | -33.0% |
| Q3 FY2024 | Sep 30, 2024 | $62.80M | -60.8% |
| Q2 FY2024 | Jun 30, 2024 | $85.90M | -54.0% |
| Q1 FY2024 | Mar 31, 2024 | $107.48M | -48.9% |
| Q4 FY2023 | Dec 31, 2023 | $137.18M | -40.4% |
| Q3 FY2023 | Sep 30, 2023 | $160.10M | +17.7% |
| Q2 FY2023 | Jun 30, 2023 | $186.90M | +23.7% |
| Q1 FY2023 | Mar 31, 2023 | $210.20M | +15.7% |
| Q4 FY2022 | Dec 31, 2022 | $230.25M | +11.0% |
| Q3 FY2022 | Sep 30, 2022 | $136.07M | -39.8% |
| Q2 FY2022 | Jun 30, 2022 | $151.09M | -38.2% |
| Q1 FY2022 | Mar 31, 2022 | $181.62M | -30.8% |
| Q4 FY2021 | Dec 31, 2021 | $207.47M | +327.4% |
| Q3 FY2021 | Sep 30, 2021 | $225.97M | +255.3% |
| Q2 FY2021 | Jun 30, 2021 | $244.63M | +235.5% |
| Q1 FY2021 | Mar 31, 2021 | $262.57M | – |
| Q4 FY2020 | Dec 31, 2020 | $48.54M | – |
| Q3 FY2020 | Sep 30, 2020 | $63.60M | – |
| Q2 FY2020 | Jun 30, 2020 | $72.91M | – |
See a number that looks wrong?